Načítá se...
2227. Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients
BACKGROUND: Short-duration with an 8-week course of ledipasvir/sofosbuvir (LDV/SOF) or glecaprevir/pibrentasvir (GLE/PIB) is considered adequate to treat hepatitis C virus (HCV) infection in selected patients. However, immunocompromised patients with HCV/HIV are not eligible for this approach. Herei...
Uloženo v:
| Vydáno v: | Open Forum Infect Dis |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6253132/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1880 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|